Clinical trial · no report yet · Phase 2
PE-PE
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
- NCT05578664 ↗
- Unknown
- Consorzio Oncotech
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Oligometastatic Renal Cell Carcinoma
- Interventions
- Pembrolizumab injection plus metastasis directed treatment (surgery or RT); Tumor resection or RT
- Arms
- ARM A · Experimental
- ARM B · Active comparator
- Enrollment
- 81 (estimated)
- Primary outcomes
- Relapsed Free Survival (RFS)
- Sponsor
- Consorzio Oncotech
- Start
- Mar 14, 2023
- Primary completion
- Oct 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05578664 · updated Aug 30, 2023